Impact of biologicals on chronic rhinosinusitis with nasal polyps in combination with severe asthma

Chronic rhinosinusitis with nasal polyps (CRSwNP) is often associated with asthma. This combination aggravates the course of both conditions, including the frequency and severity of asthma and CRSwNP exacerbations. Currently, the main strategy in the treatment of severe asthma is the use of biologicals, which may also impact CRSwNP symptoms, considering the similarity of pathogenic mechanisms of these diseases. The aim of our study was to evaluate the impact of biological therapy on CRSwNP in combination with severe asthma. Methods. 49 patients with CRSwNP and severe asthma were included in a single-center prospective cohort study. Patients were divided into 4 groups: dupilumab (n = 20), benralizumab (n = 15), mepolizumab (n = 7), and omalizumab (n = 7). Patients received the biologicals for at least 12 months (min – 12.0 months; max – 52.2 months). Asthma control (ACT, FEV₁, the number of asthma exacerbations) and CRSwNP control (SNOT-22, the number of nasal and sinus surgeries) were evaluated at baseline and during treatment. The safety of therapy was assessed by the examination results and the reported adverse events. Results. We observed statistically significant improvements in asthma control, respiratory function, and a decrease in the number of asthma exacerbations with the use of biologicals in all groups. However, there were no statistically significant differences between the groups (p > 0.05). As for CRSwNP, we found the statistically significant improvements in symptoms (ΔSNOT-22 – (–67,3) ± 23,7, p < 0,001; (–26,1) ± 24,6, p < 0,001; (–34,0) ± 23,5, p = 0,016; (–35,1) ± 25,1, p = 0,025) and a decrease in the number of surgeries after therapy (Δ number of surgeries – (–5,2) ± 8,6, p < 0,001; (–3,7) ± 3,3, p = 0,002; (–3,6) ± 2,4, p = 0,036; (–1,6) ± 1,4, p = 0,010). in all groups. At the same time, dupilumab showed a greater improvement of CRSwNP control according to the SNOT-22 questionnaire than benralizumab (p = 0.001) and mepolizumab (p = 0.034). Conclusion. Biologicals currently used to treat severe asthma have a beneficial effect on concomitant CRSwNP. However, not all biologicals are characterized by an effect on the processes of polyposis tissue remodeling and formation. Our study confirms the relevance of searching for other potential targets for the development of the new biologicals to address the identified clinical needs.

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2023. Available at: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf [Accessed: May 01, 2023].

2. Shilovskiy I.P., Eroshkina D.V., Babakhin A.A., Khaitov M.R. [Anticytokine therapy of allergic asthma]. Molekulyarnaya biologiya. 2017; 51 (1): 3–17. DOI: 10.1134/S0026893316060194 (in Russian).

3. Agache I., Beltran J., Akdis C. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75 (5): 1023–1042. DOI: 10.1111/ALL.14221.

4. Ray A., Raundhal M., Oriss T. et al. Current concepts of severe asthma. J. Clin. Invest. 2016; 126 (7): 2394–2403. DOI: 10.1172/JCI84144.

5. Bruselle G.G., Maes T., Bracke K.R. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat. Med. 2013; 19 (8): 977–979. DOI: 10.1038/NM.3300.

6. Kurbacheva O.M.., Dyneva M.E., Shilovskiy I.P. et al. [Pathogenetic molecular mechanisms of chronic rhinosinusitis with nasal polyps associated with asthma]. Pul'monologiya. 2021; 31(1): 7–19. DOI: 10.18093/0869-0189-2021-31-1-7-19 (in Russian).

7. Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): 1700634. DOI: 10.1183/13993003.00634-2017.

8. Hams E., Bermingham R., Fallon P.G. Macrophage and innate lymphoid cell interplay in the genesis of fibrosis. Front. Immunol. 2015; 6: 597. DOI: 10.3389/FIMMU.2015.00597.

9. Tashireva L.A., Zavgorodskaya K.O., Perelmuter V.M. [Role of innate lymphoid cells during cancer]. Tsitologiya. 2016; 58 (12): 901–907. Available at: http://tsitologiya.incras.ru/58_12/tashireva.pdf (in Russian).

10. Doherty T.A., Broide D.H. Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines. J. Allergy Clin. Immunol. 2018; 141 (5): 1587–1589. DOI: 10.1016/J.JACI.2018.02.034.

11. von Moltke J., O'Leary C., Barrett N. et al. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. J. Exp. Med. 2017; 214 (1): 27–37. DOI: 10.1084/JEM.20161274.

12. Allakhverdi Z., Comeau M., Jessup H. et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 2007; 204 (2): 253–258. DOI: 10.1084/JEM.20062211.

13. Khaitov M.R., Dyneva M.E., Savlevich E.L. et al. [Asthma associated with nasal polyps: clinical characteristics and analysis of local expression of IL37 gene]. Immunologiya. 2020; 41 (1): 54–63. DOI: 10.33029/0206-4952-2020-41-1-54-63 (in Russian).

14. Shilovskiy I., Dyneva M., Kurbacheva O. et al. The role of interleukin-37 in the pathogenesis of allergic diseases. Acta Naturae. 2019; 11 (4): 54–64. DOI: 10.32607/20758251-2019-11-4-54-64.

15. Fokkens W., Lund V., Bachert C. et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019; 74 (12): 2312–2319. DOI: 10.1111/all.13875.

16. Soler Z., Mace J., Litvack J. et al. Chronic rhinosinusitis, race, and ethnicity. Am. J. Rhinol. Allergy. 2012; 26 (2): 110–116. DOI: 10.2500/AJRA.2012.26.3741.

17. Hamilos D.L. Chronic rhinosinusitis: epidemiology and medical management. J. Allergy Clin. Immunol. 2011; 128 (4): 693–707. DOI: 10.1016/J.JACI.2011.08.004.

18. Khalmuratova R., Park J.W., Shin H.W. Immune cell responses and mucosal barrier disruptions in chronic rhinosinusitis. Immune Netw. 2017; 17 (1): 60–67. DOI: 10.4110/IN.2017.17.1.60.

19. Voznesenskiy N.A., Knyazheskaya N.P. [Chronic rhinosinusitis with nasal polyps and bronchial asthma: a pulmonologist's view]. Prakticheskaya pul'monologiya. 2005; (2): 32–36. Available at: https://cyberleninka.ru/article/n/polipoznyy-rinosinusit-i-bronhialnaya-astma-vzglyad-pulmonologa?ysclid=ll0l9kq0r5261804114 (in Russian).

20. Savlevich E.L., Kurbacheva O.M., Egorov V.I. et al. [Gene expression levels of cytokines in different phenotypes of CRSwNP]. Vestnik otorinolaringologii. 2019; 84 (6): 42–47. DOI: 10.17116/otorino20198406142 (in Russian).

21. Agache I., Akdis C., Akdis M. et al. EAACI biologicals guidelines – recommendations for severe asthma. Allergy. 2021; 76 (1): 14–44. DOI: 10.1111/ALL.14425.

22. Agache I., Song Y., Alonso-Coello P. et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy. 2021; 76 (8): 2337–2353. DOI: 10.1111/ALL.14809.

23. Hopkins C., Gillett S., Slack R. et al. Psychometric validity of the 22-item sinonasal outcome test. Clin. Otolaryngol. 2009; 34 (5): 447–454. DOI: 10.1111/J.1749-4486.2009.01995.X.

24. Liu W., Ma X., Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. Medicine (Baltimore). 2019; 98 (22): e15868. DOI: 10.1097/MD.0000000000015868.

25. Bachert C., Han J., Desrosiers M. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; 394 (10209): 1638–1650. DOI: 10.1016/S0140-6736(19)31881-1.

26. Bachert C., Han J., Desrosiers M. et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2022; 149 (4): 1309–1317.e12. DOI: 10.1016/J.JACI.2021.08.030.

27. Harrison T., Chanez P., Menzella F. et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir. Med. 2021; 9 (3): 260–274. DOI: 10.1016/S2213-2600(20)30414-8.

28. Han J., Bachert C., Fokkens W. et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2021; 9 (10): 1141–1153. DOI: 10.1016/S2213-2600(21)00097-7.

29. Chupp G., Bradford E., Albers F. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir. Med. 2017; 5 (5): 390–400. DOI: 10.1016/S2213-2600(17)30125-X.

30. Gevaert P., Omachi T., Corren J. et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J. Allergy Clin. Immunol. 2020; 146 (3): 595–605. DOI: 10.1016/J.JACI.2020.05.032.

31. Oykhman P., Paramo F., Bousquet J. et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J. Allergy Clin. Immunol. 2022; 149 (4): 1286–1295. DOI: 10.1016/j.jaci.2021.09.009.

32. Varricchi G., Ferri S., Pepys J.et al. Biologics and airway remodeling in severe asthma. Allergy. 2022; 77 (12): 3538–3552. DOI: 10.1111/ALL.15473.

33. Riccio A., Dal Negro R., Micheletto C. et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int. J. Immunopathol. Pharmacol. 2012; 25 (2): 475–484. DOI: 10.1177/03946320120250021.

34. Zastrzeżyńska W., Przybyszowski M., Bazan-Socha S. et al. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics. J. Asthma. 2019; 57 (5): 468–477. DOI: 10.1080/02770903.2019.1585872.

35. Roth M., Zhao F., Zhong J. et al. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and Is prevented by Omalizumab. PLoS One. 2015; 10 (9): e0136549. DOI: 10.1371/JOURNAL.PONE.0136549.

36. Flood-Page P., Menzies-Gow A., Phipps S. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 2003; 112 (7): 1029–1036. DOI: 10.1172/JCI17974.

37. Chachi L., Diver S., Kaul H. et al. Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur. Respir. J. 2019; 54 (5): 1900930. DOI: 10.1183/13993003.00930-2019.